Industry landscapes
The companies, capital and talent shaping life sciences in Singapore. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
17 of 388 tracked companies have open roles.
80 of 388 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 100 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 45.3% of disclosed capital, while 79.4% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $156.49M | 26 | 4 |
| 2017 | $22.29M | 20 | 7 |
| 2018 | $124.56M | 28 | 7 |
| 2019 | $111.66M | 28 | 6 |
| 2020 | $84.44M | 27 | 11 |
| 2021 | $623.93M | 24 | 15 |
| 2022 | $560.02M | 20 | 11 |
| 2023 | $171.8M | 13 | 12 |
| 2024 | $72.14M | 10 | 8 |
| 2025 | $88.73M | 5 | 8 |
Share of all disclosed company funding.
145 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Clavystbio and ZIG Ventures.
Backed by Goldman Sachs Asset Management and Pavilion Capital Partners and others.
Participating investors were not recorded in this snapshot.
Backed by Novo Holdings and Frazier Healthcare Partners and others.
Participating investors were not recorded in this snapshot.
Participating investors were not recorded in this snapshot.
Backed by Rock Springs Capital and EDBI and others.
Participating investors were not recorded in this snapshot.
Backed by Rock Springs Capital and Charoen Pokphand Group and others.
Backed by Joy Capital and Chuangxin Innovation Works and others.
Backed by Prosperity7 Ventures and SoftBank Vision Fund and others.
No reviewed exact national-ID connector has yet been qualified for Singapore; this is a checked implementation boundary, not evidence that filings are absent.; No reviewed exact national-ID connector has yet been qualified for Singapore; this is a checked implementation boundary, not evidence that filings are absent.
How the Singapore companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
14 of these companies (3.6%) publish at least one Android app — 17 apps in all, carrying 113.2K installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Zenyumzenyum | 52.8K | 3.9 | Beauty |
| Life AILIFE AI | 50.1K | — | Health & Fitness |
| WWC-SCANBOScanbo | 4.1K | — | Health & Fitness |
| MedCheckMedcheck | 3.2K | — | Health & Fitness |
| Nala Personal Health ManagerNalagenetics | 1.6K | — | Health & Fitness |
| Syai EssentialSyai | 976 | — | Medical |
| HFM AppMedTech | 184 | — | Medical |
| SMILE - Baby MilestonesGarden Genesis | 66 | — | Parenting |
| HFM App (Doctor)MedTech | 48 | — | Medical |
| PreSAGEPreSAGE | 43 | — | Productivity |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q4–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 9 | 8.6K | WWC-SCANBO 4.1K | |
| Wearable Technology | 8 | 8.6K | MedCheck 3.2K | |
| Healthcare It | 6 | 4.4K | HFM App 184 | |
| Cardiac And Vascular Disorders | 6 | 4.4K | HFM App (Doctor) 48 | |
| Diabetes | 2 | 4.2K | Syai Essential 976 | |
| Genomics | 3 | 1.7K | Nala Personal Health Manager 1.6K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
12 companies hiring · $2B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Logice, Sembuh AI and StratifiCare each awarded S$500,000 by major Japan IT company TIS Inc., as part of its S$7.6 million commitment to co-develop and scale the accelerator programme.
iX Biopharma completed a placement on Feb 24, issuing 75.8 million new shares to raise gross proceeds of S$15 million.
2 months ago Singapore-based consumer dental firm Zenyum and India’s MakeO Toothsi said on Wednesday that they were planning to merge
Nanyang Biologics Pte. Ltd., a Singapore-based drug discovery company backed by The9 Limited, announced that it will go public through a business combination with RF Acquisition Corp II. The transaction values Nanyang Biologics at approximately $1.5 billion.
Biolidics, listed in 2018, now trades at a price that reflects a drop of more than 90 per cent from its IPO level.
"Clearbridge Health, a Singapore-listed healthcare company, has raised SGD 1.98 million (USD 1.5 million) through a private placement of shares."
IPOs in May 2025: Mirxes, Antalpha, and Oasis Home went public.
Singapore / Bangkok, May 13, 2025 – (ACN Newswire) – Thailand-listed Medeze Group Public Company Limited (“Medeze”, together with its subsidiaries, the “Medeze Group”), through its wholly owned subsidiary Medeze Treasury Pte. Ltd. (the “Offeror”), intends to make a voluntary conditional cash partial offer (the “Partial Offer”) to acquire 10.00% of the issued ordinary shares of Cordlife Group Limited (“Cordlife” or the “Offeree”), a Singapore-listed provider of cord blood banking services.
Angelini Ventures, the corporate venture company of Angelini Industries, has a series B financing round of 45 million euros.
Aslan previously raised $12 million in a 2011 series A round
Top 10 categories among 77 recorded events in the 24-month window.
4 companies with recorded IPO activity
IPO · HKEX9 reports
IPO · SGX1 reports
IPO · SGX1 reports
IPO · Toronto Stock Exchange2 reports
3 tracked people moves
Appointment Chief Executive Officer
Promotion Executive Chairman
Resignation Previously Chairman
2 recorded customer wins
Customer: ferringPharmaceuticals
Customer: CSL Ltd.Biotechnology
25 recorded events
licence renewedMinistry of Health
renewed for another yearMinistry of Health
restricted from accepting new CBUsMinistry of Health
suspended for six monthsMinistry of Health
Reported company results in the recorded window.
Median across 11 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Zenyum→makeo | Announced | 2026-02-28 | Not stated in snapshot |
| makeo→Zenyum ↗ | Announced | 2026-02-10 | Not stated in snapshot |
| RF Acquisition Corp II→Nanyang Biologics ↗ | Announced | 2025-10-02 | $1.5B |
| medeze group→Cordlife ↗ | Announced | 2025-05-13 | Not stated in snapshot |
| Clearbridge Health→elpis biopharmaceuticals | Announced | 2025-04-22 | $330.0M |
| MerLion Pharmaceuticals→combinature biopharm | Completed | 2025-02-14 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
24 postings in the preceding 12 months. The full 69-posting snapshot covers 42 employers.
0 tracked postings mention remote work.
19 postings specify a level.
Top skills across 69 tracked postings in the available jobs snapshot.
Median across 54 postings with pay data, expressed in USD.
| Company | Employees |
|---|---|
| Mirxes ↗ | 400 |
| SciGen ↗ | 201 |
| transcend ↗ | 118 |
| Cordlife ↗ | 111 |
| Lucence ↗ | 91 |
| iX Biopharma ↗ | 68 |
| Nalagenetics ↗ | 62 |
| BioMind ↗ | 60 |
289 founders and chief executives across 200 companies.
University of Aberdeen
Ex-RIGOL Technologies. Xi'an Jiaotong University BE 2008
Ex-AABC, Inventages Venture Capital, Flexycast · UCL BSc, King's College London MBBS, Imperial College London MSc, The Wharton School MBA 2010…
Co-Founder MiRXES, ex-biotech company, icroRNA technologies. National University of Singapore PhD 2012
INSEAD MBA, Imperial College London MSc, PhD
Co-Founder MotusAcademy, IISART, ex-Hocoma Asia Pacific Office in Singapore, Singapore National Co-operative Federation. University of Strathclyde…
Ex-XyloCor Therapeutics, GSK · University of Delaware BS, Drexel University MBA
PairX Bio, Nest.Bio Ventures, Goodman Capital, ex-Enleofen Bio, AirAsia. University of Pennsylvania
Agricultural University of Jilin 2008, University of Coimbra MBA 2014
Aum Biosciences, ex-Eps Corporation A Full Service Japan Headquartered Cro, ex-Icon, Kingston University, 2007
ex- Isfahan University of Technology, Co-Founder C door. Isfahan University of Technology 2012, National University of Singapore PhD 2017
Ex- Managing Director Trinity Innovation Bioventure Singapore, CEO Shanghai Blueray Biopharma. Chinese Academy of Sciences PhD 2005…
87 profiles with education records.
4 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
301,618 articles in the measured 12-month window.
Life Sciences coverage across Singapore · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 39,272 |
| 2021Q3 | 43,470 |
| 2021Q4 | 39,582 |
| 2022Q1 | 42,863 |
| 2022Q2 | 43,986 |
| 2022Q3 | 49,305 |
| 2022Q4 | 54,984 |
| 2023Q1 | 57,179 |
| 2023Q2 | 56,317 |
| 2023Q3 | 57,224 |
| 2023Q4 | 62,825 |
| 2024Q1 | 60,927 |
| 2024Q2 | 71,420 |
| 2024Q3 | 69,955 |
| 2024Q4 | 73,002 |
| 2025Q1 | 87,015 |
| 2025Q2 | 56,567 |
| 2025Q3 | 150,443 |
| 2025Q4 | 45,615 |
| 2026Q1 | 51,501 |
Article volume measures coverage, not market sales.
207 recorded company events across 31 companies; percentages use that event total.
Life Sciences coverage across Singapore · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across Singapore
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| countries | 4,192 | 1,858 | 126% |
| stablecoin fx impact | 687 | 306 | 125% |
| decentralized forex | 675 | 402 | 68% |
| study overseas | 593 | 188 | 215% |
| overseas study | 540 | 176 | 207% |
| semester abroad | 473 | 146 | 224% |
| international programs | 345 | 97 | 256% |
| tanker routing | 322 | 53 | 508% |
| aframax tankers | 318 | 68 | 368% |
| export sanctions | 285 | 97 | 194% |
| flight safety measures | 128 | 519 | -75% |
| f1 world championship | 324 | 509 | -36% |
| f1 championship | 302 | 477 | -37% |
| direct investments (pe) | 266 | 440 | -40% |
| brent crude forecast | 92 | 424 | -78% |
Life Sciences coverage across Singapore
territories, disputed islands, countries
18.3% critical · 15.9% positiveinflation reports fx, currency intervention policies, pre-ipo valuation
41.1% critical · 58.7% positivegdp growth forex, gdp growth rate, inflation reports fx
39.4% critical · 51.8% positiveLife Sciences coverage across Singapore. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Challenges in using microbes and plants for renewable fuels and biorefinery processes.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.6 |
| 2023 | 59.3 |
| 2024 | 61.9 |
| 2025 | 67.0 |
Common problems researchers identify · 0216.8% of this theme group
Issues surrounding microbial hazards, nutritional quality, and health impacts of processed foods.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 70.2 |
| 2023 | 72.4 |
| 2024 | 77.4 |
| 2025 | 99.2 |
Common problems researchers identify · 0315.8% of this theme group
Difficulties in controlling gene expression and metabolic profiling in laboratory and veterinary models.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2510.1 |
| 2023 | 2495.8 |
| 2024 | 2199.0 |
| 2025 | 1697.8 |
Common problems researchers identify · 0415.4% of this theme group
Barriers to improving nutrient uptake, germplasm efficiency, and stable food supplies.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1635.2 |
| 2023 | 1667.4 |
| 2024 | 1799.9 |
| 2025 | 2026.9 |
Common problems researchers identify · 0515.3% of this theme group
Complexities of host immunity, pathogen interactions, and integrated control strategies.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.8 |
| 2023 | 29.2 |
| 2024 | 27.8 |
| 2025 | 37.2 |
Common problems researchers identify · 069.9% of this theme group
Rising resistance in humans, livestock, and the environment threatening treatment effectiveness.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.4% of this theme group
Broad, unrelated research areas lacking a clear thematic focus.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.4 |
| 2023 | 21.9 |
| 2024 | 17.8 |
| 2025 | 12.5 |
Cautions · 0121.5% of this theme group
Need for careful interpretation of in‑vitro and in‑vivo stress measurements.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1034.9 |
| 2023 | 1110.3 |
| 2024 | 911.7 |
| 2025 | 818.5 |
Cautions · 0214.6% of this theme group
Caution about translating breeding models into reliable agricultural outcomes.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1437.3 |
| 2023 | 1478.4 |
| 2024 | 1637.4 |
| 2025 | 1817.4 |
Cautions · 0313.9% of this theme group
Potential unintended effects of bioactive compounds on livestock health and sustainability.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 22.2 |
| 2023 | 20.9 |
| 2024 | 17.3 |
| 2025 | 18.2 |
Cautions · 0413.6% of this theme group
Uncertainties surrounding novel ingredients, additives, and their compliance with safety standards.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 91.3 |
| 2023 | 89.1 |
| 2024 | 95.4 |
| 2025 | 105.8 |
Cautions · 0513.5% of this theme group
Complexities in interpreting gene‑expression changes linked to genomic instability.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2415.6 |
| 2023 | 2417.4 |
| 2024 | 2125.5 |
| 2025 | 1613.8 |
Cautions · 0611.7% of this theme group
Risks of cross‑resistance among antibiotics, biocides, and heavy metals in food systems.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Cautions · 0711.3% of this theme group
Challenges in managing resistance while integrating low‑dose and biological pest strategies.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.9 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 75.8 |
Opportunities · 0117.4% of this theme group
Promising methods for in‑vivo labeling, fluorescence, and flow‑based immune analyses.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 561.4 |
| 2023 | 615.1 |
| 2024 | 467.1 |
| 2025 | 455.3 |
Opportunities · 0217.2% of this theme group
Opportunities in modulating apoptosis, knockdown, and cell growth for therapeutic benefit.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0314.6% of this theme group
Emerging health‑focused ingredients and antioxidants for sustainable nutrition.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 26.2 |
| 2024 | 27.1 |
| 2025 | 45.2 |
Opportunities · 0413.7% of this theme group
Innovations in DNA methylation profiling and messenger‑RNA detection for disease monitoring.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2397.7 |
| 2023 | 2377.6 |
| 2024 | 2114.7 |
| 2025 | 1613.7 |
Opportunities · 0513.5% of this theme group
New plant‑derived agents and microbial products to combat resistance and improve animal health.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.4 |
| 2024 | 554.5 |
| 2025 | 649.8 |
Opportunities · 0611.9% of this theme group
Leveraging germplasm and quantitative trait loci to boost yield and resilience.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 53.0 |
| 2023 | 45.3 |
| 2024 | 39.2 |
| 2025 | 40.8 |
Opportunities · 0711.6% of this theme group
Integrating microbial fermentation and agri‑food by‑products for greener energy and materials.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1514.8 |
| 2023 | 1566.1 |
| 2024 | 1742.6 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.9% |
| Promising | 30.4% | 37.0% |
| Breakthrough | 14.1% | 26.3% |
| Problem-identifying | 8.3% | 9.5% |
| Cautionary | 3.5% | 4.5% |
| Comparative | 2.4% | 3.9% |
| Critical | 1.0% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 3 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗